2003–2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer

Immunology Letters

Volumn 183, Issue , 2017, Pages 37-43

  Lin, Mao ^a,b   Liang, Shuzhen ^a,b   Jiang, Feng ^b   Xu, Jiongyuan ^a   Zhu, Weibing ^a   Qian, Wei ^a   Hu, Yong ^a   Zhou, Zhanchun ^a   Chen, Jibing ^a,b   Niu, Lizhi ^b   Xu, Kecheng ^b   Lv, Youyong ^c  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^b Guangzhou ^*  (China)

^c PEKING UNIVERSITY   (China)

Author keywords

Cytokine induced killer; Dendritic cell; DFS; Immunotherapy; OS; Stage IV breast cancer

Indexed keywords

CARMOFUR; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; TUMOR ANTIGEN; CANCER VACCINE; CYTOKINE;

ADULT; ADVERSE OUTCOME; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL ISOLATION; CELL THERAPY; CHILL; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DISTANT METASTASIS; EDEMA; FATIGUE; FEVER; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INJECTION SITE REACTION; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSPECTIVE STUDY; RISK REDUCTION; TUMOR RECURRENCE; AGED; BREAST TUMOR; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MORTALITY; MULTIMODALITY CANCER THERAPY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; CYTOKINES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85011579991     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2017.01.014     Document Type: Article

References (37)

1. [1] Rabbani, S.A., Mazar, A.P., Evaluating distant metastases in breast cancer: from biology to outcomes. Cancer Metastasis Rev. 26 (2007), 663–674.
2. [2] Valastyan, S., Weinberg, R.A., Tumor metastasis: molecular insights and evolving paradigms. Cell 147 (2011), 275–292.
3. [3] Andre, F., Slimane, K., Bachelot, T., Dunant, A., Namer, M., Barrelier, A., et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J. Clin. Oncol. 22 (2004), 3302–3308.
4. [4] Chia, S.K., Speers, C.H., D'Yachkova, Y., Kang, A., Malfair-Taylor, S., Barnett, J., et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110 (2007), 973–979.
5. [5] Gennari, A., Conte, P., Rosso, R., Orlandini, C., Bruzzi, P., Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104 (2005), 1742–1750.
6. [6] Frankenberger, B., Schendel, D.J., Third generation dendritic cell vaccines for tumor immunotherapy. Eur. J. Cell Biol. 91 (2012), 53–58.
7. [7] Melief, C.J., Cancer: immune pact with the enemy. Nature 450 (2007), 803–804.
8. [8] Timmerman, J.M., Czerwinski, D.K., Davis, T.A., Hsu, F.J., Benike, C., Hao, Z.M., et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99 (2002), 1517–1526.
9. [9] Nestle, F.O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4 (1998), 328–332.
10. [10] Fong, L., Hou, Y., Rivas, A., Benike, C., Yuen, A., Fisher, G.A., et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 8809–8814.
11. [11] Higano, C.S., Schellhammer, P.F., Small, E.J., Burch, P.A., Nemunaitis, J., Yuh, L., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115 (2009), 3670–3679.
12. [12] Nabhan, C., Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363 (2010), 1966–1968 author reply 8.
13. [13] Kantoff, P.W., Higano, C.S., Small, E.J., Whitmore, J.B., Frohlich, M.W., Schellhammer, P.F., Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J. Natl. Cancer Inst. 104 (2012), 1107–1109 author reply 9–12.
14. [14] Huber, M.L., Haynes, L., Parker, C., Iversen, P., Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J. Natl. Cancer Inst. 104 (2012), 273–279.
15. [15] Frohlich, M.W., Sipuleucel-T for the treatment of advanced prostate cancer. Semin. Oncol. 39 (2012), 245–252.
16. [16] Gutgemann, S., Frank, S., Strehl, J., Schmidt-Wolf, I.G., Cytokine-induced killer cells are type II natural killer T cells. German Med. Sci., 5, 2007, Doc07.
17. [17] Lu, P.H., Negrin, R.S., A novel population of expanded human CD3 + CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol. 153 (1994), 1687–1696.
18. [18] Margolin, K.A., Negrin, R.S., Wong, K.K., Chatterjee, S., Wright, C., Forman, S.J., Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol. Rev. 157 (1997), 231–240.
19. [19] Linn, Y.C., Hui, K.M., Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia. Leukemia lymphoma 44 (2003), 1457–1462.
20. [20] Hontscha, C., Borck, Y., Zhou, H., Messmer, D., Schmidt-Wolf, I.G., Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J. Cancer Res. Clin. Oncol. 137 (2011), 305–310.
21. [21] Gonzalez-Carmona, M.A., Marten, A., Hoffmann, P., Schneider, C., Sievers, E., Schmidt-Wolf, I.G., et al. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells. Liver Int. 26 (2006), 369–379.
22. [22] Marten, A., Greten, T., Ziske, C., Renoth, S., Schottker, B., Buttgereit, P., et al. Generation of activated and antigen-specific T cells with cytotoxic activity after co-culture with dendritic cells. Cancer Immunol. Immunother. 51 (2002), 25–32.
23. [23] Marten, A., Ziske, C., Schottker, B., Weineck, S., Renoth, S., Buttgereit, P., et al. Transfection of dendritic cells (DCs) with the CIITA gene: increase in immunostimulatory activity of DCs. Cancer Gene Ther. 8 (2001), 211–219.
24. [24] Su, X., Zhang, L., Jin, L., Ye, J., Guan, Z., Chen, R., Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells. J. Clin. Immunol. 30 (2010), 766–774.
25. [25] Sun, Y., Chen, J., Cai, P., Hu, Y.H., Zhong, G.C., Feng, H.Z., et al. Therapy of relapsed or refractory non-Hodgkin's lymphoma by antigen specific dendritic cells-activated lymphocytes. Zhongguo shi yan xue ye xue za zhi/Zhongguo bing li sheng li xue hui = J. Exp. Hematol. Chin. Assoc. Pathophysiol. 18 (2010), 219–223.
26. [26] Leemhuis, T., Wells, S., Scheffold, C., Edinger, M., Negrin, R.S., A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol. Blood Marrow Transpl. 11 (2005), 181–187.
27. [27] Li, H., Wang, C., Yu, J., Cao, S., Wei, F., Zhang, W., et al. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy 11 (2009), 1076–1083.
28. [28] Pan, Y., Zhang, J., Zhou, L., Zuo, J., Zeng, Y., In vitro anti-tumor immune response induced by dendritic cells transfected with EBV-LMP2 recombinant adenovirus. Biochem. Biophys. Res. Commun. 347 (2006), 551–557.
29. [29] Morse, M.A., Deng, Y., Coleman, D., Hull, S., Kitrell-Fisher, E., Nair, S., et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res. 5 (1999), 1331–1338.
30. [30] O'Neill, D., Bhardwaj, N., Exploiting dendritic cells for active immunotherapy of cancer and chronic infection. Methods Mol. Med. 109 (2005), 1–18.
31. [31] O'Neill, D.W., Bhardwaj, N., Exploiting dendritic cells for active immunotherapy of cancer and chronic infections. Mol. Biotechnol. 36 (2007), 131–141.
32. [32] Banchereau, J., Steinman, R.M., Dendritic cells and the control of immunity. Nature 392 (1998), 245–252.
33. [33] van Broekhoven, C.L., Parish, C.R., Demangel, C., Britton, W.J., Altin, J.G., Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res. 64 (2004), 4357–4365.
34. [34] Schlom, J., Recent advances in therapeutic cancer vaccines. Cancer Biother. Radiopharm. 27 (2012), 2–5.
35. [35] Duru, N., Fan, M., Candas, D., Menaa, C., Liu, H.C., Nantajit, D., et al. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin. Cancer Res. 18 (2012), 6634–6647.
36. [36] Li, C.D., Zhang, W.Y., Li, H.L., Jiang, X.X., Zhang, Y., Tang, P.H., et al. Mesenchymal stem cells derived from human placenta suppress allogeneic umbilical cord blood lymphocyte proliferation. Cell Res. 15 (2005), 539–547.
37. [37] Beutler, N., Hauka, S., Niepel, A., Kowalewski, D.J., Uhlmann, J., Ghanem, E., et al. A natural tapasin isoform lacking exon 3 modifies peptide loading complex function. Eur. J. Immunol. 43 (2013), 1459–1469.